Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.


  Ophthalmology

  Free Subscription


Articles published in J Ocul Pharmacol Ther

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    May 2025
  1. LACAU S, Marin A, Bitrian E
    Steroid-Induced Ocular Hypertension in Children: A Review on Risk Factors.
    J Ocul Pharmacol Ther. 2025 May 13. doi: 10.1089/jop.2025.0024.
    PubMed     Abstract available


  2. AFTAB OM, Khan H, Aftab B, Haque W, et al
    Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study.
    J Ocul Pharmacol Ther. 2025 May 5. doi: 10.1089/jop.2024.0178.
    PubMed     Abstract available


  3. SHARMA A, Sharma PK, Kompella UB
    Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine.
    J Ocul Pharmacol Ther. 2025;41:173-186.
    PubMed     Abstract available


  4. NAVARRO-NARANJO PI, Chacon-Aponte A, Artunduaga-Rodriguez G
    Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease.
    J Ocul Pharmacol Ther. 2025;41:210-216.
    PubMed     Abstract available


    April 2025
  5. FAHMY A, Ahmed M, Pflugfelder S, Serikbaeva A, et al
    Comparative Efficacy of Current Topical Treatments for Dry Eye Disease: A Review of Pivotal Clinical Trials Evaluating Corneal Staining Outcomes.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0192.
    PubMed     Abstract available


  6. LIU J, Jiang E, Kim H, Moon J, et al
    Beneficial Effect of Rebamipide Eye Drops on Blue Light-Induced Oxidative Damage in the Ocular Surface.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0208.
    PubMed     Abstract available


  7. SANCHEZ-TOCINO H, Villanueva Gomez A, Saldana Burgos R, Hata Viveiros MM, et al
    Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0202.
    PubMed     Abstract available


  8. QUIRKE M, Lamoureux F, Arnoult C, Gress G, et al
    Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0165.
    PubMed     Abstract available


  9. PETTY RM, Rangan RS, Curry S, Brooks CD, et al
    Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0191.
    PubMed     Abstract available


  10. DUTRA BAL, Wilson SE
    Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity.
    J Ocul Pharmacol Ther. 2025 Apr 16. doi: 10.1089/jop.2024.0200.
    PubMed     Abstract available


  11. REITINGER JC, Reed DM, Peres C, Fan S, et al
    Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.
    J Ocul Pharmacol Ther. 2025 Apr 14. doi: 10.1089/jop.2024.0112.
    PubMed     Abstract available


  12. JIN H, Yoon HJ, Jiang E, Liu J, et al
    Therapeutic Effects of Human Placental Extracts Eye Drops in Experimental Dry Eye and Alkali Burn.
    J Ocul Pharmacol Ther. 2025;41:141-149.
    PubMed     Abstract available


    March 2025
  13. KISHI A, Bryant AD, Reed DM, Toris CB, et al
    Letter to the Editor: Effect of Aqueous Tears on Topical Fluorescein Tracer Emission Signal from Cornea and Anterior Chamber.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0143.
    PubMed    


  14. PUTRI LR, Edwar L
    Corticosteroid as Treatment in Infective Conjunctivitis: A Systematic Literature Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0110.
    PubMed     Abstract available


  15. AFTAB OM, Khan H, Bargoud A, Khouri AS, et al
    Are Alpha-2 Adrenergic Agonists Being Used in Infants?
    J Ocul Pharmacol Ther. 2025;41:75-78.
    PubMed     Abstract available


    February 2025
  16. ROUTH BL, Tripathi R, Giuliano EA, Lankau BR, et al
    Effect of Chemical Injury on Autophagy in Canine Corneal Stromal Fibroblasts.
    J Ocul Pharmacol Ther. 2025 Feb 17. doi: 10.1089/jop.2024.0211.
    PubMed     Abstract available


  17. ALEKSANDER-IVANOV Y, Amaral DC, Cheidde L, Lima GN, et al
    Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    J Ocul Pharmacol Ther. 2025 Feb 10. doi: 10.1089/jop.2024.0169.
    PubMed     Abstract available


  18. VOUGHT R, Vought V, Crane AB, Khouri AS, et al
    Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0196.
    PubMed     Abstract available


  19. HONG S, Woo M, Eom Y, Kim HK, et al
    A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0160.
    PubMed     Abstract available


  20. SADIKAN MZ, Lambuk L, Reshidan NH, Abdul Ghani NA, et al
    Age-Related Macular Degeneration Pathophysiology and Therapeutic Potential of Tocotrienols: An Update.
    J Ocul Pharmacol Ther. 2025 Feb 3. doi: 10.1089/jop.2024.0123.
    PubMed     Abstract available


    January 2025
  21. COSKUN A, Senturk F, Turan E
    Enhanced Transepithelial Riboflavin Delivery Across the Cornea Using Magnetic Nanocarriers.
    J Ocul Pharmacol Ther. 2025 Jan 30. doi: 10.1089/jop.2024.0183.
    PubMed     Abstract available


  22. SARKAR T, Gogoi NR, Jana BK, Mazumder B, et al
    Formulation Advances in Posterior Segment Ocular Drug Delivery.
    J Ocul Pharmacol Ther. 2025 Jan 23. doi: 10.1089/jop.2024.0153.
    PubMed     Abstract available


  23. CRUZ MRB, Amaral DC, Goncalves OR, Cyrino LG, et al
    Chlorhexidine Compared with Povidone-Iodine in Intravitreal Injection: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Jan 21. doi: 10.1089/jop.2024.0141.
    PubMed     Abstract available


  24. GRESS G, Lamoureux F, Bourgain J, Ganem A, et al
    Selective Tissue Penetration of the Corneal Layers of Cyclosporin 2% Associated with Miglyol in Rabbits.
    J Ocul Pharmacol Ther. 2025 Jan 20. doi: 10.1089/jop.2024.0087.
    PubMed     Abstract available


  25. SADIKAN MZ, Lambuk L, Reshidan N, Ahmad Hairi H, et al
    Molecular Mechanisms of Vitamin E in Ocular Neurodegenerative Disorders: An Update on the Emerging Evidence and Therapeutic Implications.
    J Ocul Pharmacol Ther. 2025 Jan 8. doi: 10.1089/jop.2024.0125.
    PubMed     Abstract available


  26. HOARAU G, Best AL, Zina-Meziou S, Benali-Abdallah M, et al
    Effects of Intense Pulsed Light on Presumed Neuropathic Pain Associated with Meibomian Gland Dysfunction: A Before-After Study.
    J Ocul Pharmacol Ther. 2025;41:24-32.
    PubMed     Abstract available


    December 2024
  27. IRFAN AMSM, Geoffrey S, Htet H, Krishnappa P, et al
    N-Methyl-d-Aspartate-Induced Excitotoxicity and Its Impact on the Renin-Angiotensin System in Retinal Tissue.
    J Ocul Pharmacol Ther. 2024 Dec 13. doi: 10.1089/jop.2024.0131.
    PubMed     Abstract available


  28. KOVALIS N, Graffi S, Safuri S, Shapira Y, et al
    Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.
    J Ocul Pharmacol Ther. 2024;40:675-679.
    PubMed     Abstract available


  29. YAN YL, Chang JY, Ling XR, Xue CY, et al
    Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2024;40:629-637.
    PubMed     Abstract available


  30. WANG N, Yuan K, Yang S, Jin X, et al
    13-cis Retinoic Acid-Mediated Modulation of Human Meibomian Gland Epithelial Cells Development: Implications for In Vitro Modeling of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:659-667.
    PubMed     Abstract available


  31. BHUJBAL S, Rupenthal ID, Steven P, Agarwal P, et al
    Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments.
    J Ocul Pharmacol Ther. 2024;40:638-658.
    PubMed     Abstract available


  32. SEETHARAMAN ATM, Owens CE, Gangaraju R
    Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits.
    J Ocul Pharmacol Ther. 2024;40:617-628.
    PubMed     Abstract available


    November 2024
  33. ERB C, Topouzis F, Jayaram H, Allan F, et al
    Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension.
    J Ocul Pharmacol Ther. 2024 Nov 7. doi: 10.1089/jop.2024.0092.
    PubMed     Abstract available


  34. ROWE-RENDLEMAN CL
    Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1.
    J Ocul Pharmacol Ther. 2024 Nov 4. doi: 10.1089/jop.2024.0151.
    PubMed    


  35. NGUYEN A, Naidoo KK, Ajouz L, Xu X, et al
    Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:562-570.
    PubMed     Abstract available


    October 2024
  36. HWANG JS, Song HB, Lee G, Jeong S, et al
    Extracellular Vesicles Derived from Adipose-Derived Mesenchymal Stem Cells Alleviate Apoptosis and Oxidative Stress of Retinal Pigment Epithelial Cells Through Activation of Nrf2 Signaling Pathway.
    J Ocul Pharmacol Ther. 2024 Oct 25. doi: 10.1089/jop.2024.0064.
    PubMed     Abstract available


  37. DIBAS A, Batabyal S, Kim S, Carlson M, et al
    Efficacy of Intravitreal Multi-Characteristic Opsin (MCO-010) Optogenetic Gene Therapy in a Mouse Model of Leber Congenital Amaurosis.
    J Ocul Pharmacol Ther. 2024 Oct 23. doi: 10.1089/jop.2024.0084.
    PubMed     Abstract available


  38. BOUHAJIB M, Tayab Z, Di Marco C, Suh DD, et al
    Clinical Pharmacokinetics of Atropine Administered Ocularly Using an Ultrasensitive Bioanalytical Assay.
    J Ocul Pharmacol Ther. 2024 Oct 4. doi: 10.1089/jop.2024.0113.
    PubMed     Abstract available


  39. SULTAN A, Harris DL, Lam P, Whitcomb J, et al
    The Optejet Technology Minimizes Preservative-Mediated Cytotoxicity of Conjunctival Epithelial Cells Treated with Latanoprost In Vitro.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0085.
    PubMed     Abstract available


  40. HILL M, Andrews-Pfannkoch C, Atherton E, Knudsen T, et al
    Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0130.
    PubMed     Abstract available


  41. MATSUMOTO R, Obata S, Kakinoki M, Sawada O, et al
    Duration of Vascular Endothelial Growth Factor Suppression after Intravitreal Injection of Faricimab in Macaque Eyes.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0138.
    PubMed     Abstract available


    September 2024
  42. JUAN HY, Sheu SJ, Hwang DK
    Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis.
    J Ocul Pharmacol Ther. 2024 Sep 24. doi: 10.1089/jop.2024.0100.
    PubMed     Abstract available


  43. LUHAR M, Viradiya R, Panjabi S, Patel G, et al
    Nanotechnology in Ocular Drug Delivery: The Potential of Polymeric Micelles as a Drug Delivery Vehicle.
    J Ocul Pharmacol Ther. 2024 Sep 12. doi: 10.1089/jop.2024.0060.
    PubMed    


  44. TSENG KA
    Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Journal of Ocular Pharmacology and Therapeutics.
    J Ocul Pharmacol Ther. 2024;40:407.
    PubMed    


  45. FUKUDA M, Kiyoi T, Takeda S, Sasaki Y, et al
    Preventative Effect of Topical Rebamipide Against Corneal Epithelium Disorders Caused by Diclofenac Sodium.
    J Ocul Pharmacol Ther. 2024;40:428-434.
    PubMed     Abstract available


  46. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:408-409.
    PubMed    


  47. ZHAO Y, Zhang X, Zhou X, Chen B, et al
    IL-22/IL-22RA1 Promotes Human Tenon's Capsule Fibroblasts Proliferation and Regulates Fibrosis Through STAT3 Signaling Pathway.
    J Ocul Pharmacol Ther. 2024;40:435-444.
    PubMed     Abstract available


    August 2024
  48. GAO AY, Whaley MG, Saraf N, Bakri SJ, et al
    Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics.
    J Ocul Pharmacol Ther. 2024 Aug 29. doi: 10.1089/jop.2024.0006.
    PubMed     Abstract available


  49. DURRANI AF, Momenaei B, Soni V, Tennant M, et al
    Long-Term Stability, Sterility, And Cost-Effectiveness of 0.05% Chlorhexidine Gluconate as Antisepsis for Intravitreal Injection.
    J Ocul Pharmacol Ther. 2024 Aug 22. doi: 10.1089/jop.2024.0071.
    PubMed     Abstract available


  50. BACHARACH J, McLaurin EB, Silverstein S, Amrane M, et al
    Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.
    J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0029.
    PubMed     Abstract available


  51. CREAN CS, Yeu E, Maiti S, Neervannan S, et al
    Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.
    J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0074.
    PubMed     Abstract available


    July 2024
  52. WON J, Kang J, Kang W
    Comparative Ocular Pharmacokinetics of Dexamethasone Implants in Rabbits.
    J Ocul Pharmacol Ther. 2024 Jul 24. doi: 10.1089/jop.2024.0052.
    PubMed    


  53. HAMEED SS, Bodi NE, Miller RC, Sharma TP, et al
    Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model.
    J Ocul Pharmacol Ther. 2024 Jul 12. doi: 10.1089/jop.2024.0041.
    PubMed     Abstract available


  54. ZEMITIS A, Vanags J, Fan J, Klavins K, et al
    Metabolomic Disparities in Intraocular Fluid Across Varied Stages of Cataract Progression: Implications for the Analysis of Cataract Development.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0067.
    PubMed     Abstract available


  55. CHAUVIER J, Trone MC, Gain P, Ollier E, et al
    Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0023.
    PubMed     Abstract available


  56. KASHIKAR R, Senapati S, Dudhipala N, Basu SK, et al
    Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0055.
    PubMed     Abstract available


  57. DOLAN K, Liao SM, Crowley M, Xiang C, et al
    Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0046.
    PubMed     Abstract available


  58. ZOR KR, Yilmaz U, Bozkurt SB
    Coenzyme Q10 and Vitamin E Regulate the Bioactivity of Human Corneal Fibroblast Cells.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0050.
    PubMed     Abstract available


  59. MENG C, Wei Q, Gu C, He S, et al
    Prevalence and Risk Factors of Ocular Demodex at Ultra-High Altitude and Sea Level: A Cross-Sectional Study of Shigatse and Shanghai.
    J Ocul Pharmacol Ther. 2024 Jul 4. doi: 10.1089/jop.2024.0038.
    PubMed     Abstract available


  60. PAGNACCO C, Tosi R, Dalsaso J, Fraccaroli S, et al
    A Prospective, Randomized, Controlled Clinical Investigation Comparing the Efficacy and Safety of Sodium Hyaluronate-Based Ophthalmical Viscosurgical Devices FIDIAL PLUS and IAL((R))-F in Cataract Surgery.
    J Ocul Pharmacol Ther. 2024 Jul 1. doi: 10.1089/jop.2024.0044.
    PubMed     Abstract available


  61. YAO Q, Wu H, Ren H, Cao J, et al
    Inhibition of Experimental Corneal Neovascularization by the Tight Junction Protein ZO-1.
    J Ocul Pharmacol Ther. 2024;40:379-388.
    PubMed     Abstract available


  62. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:325-326.
    PubMed    


  63. MICHAEL E, Singh V
    Diagnostic Uses of Common Eye Drops.
    J Ocul Pharmacol Ther. 2024;40:327-331.
    PubMed     Abstract available


    June 2024
  64. KLEINMAN D, Iqbal S, Ghosh AK, Ogle SD, et al
    PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro.
    J Ocul Pharmacol Ther. 2024 Jun 27. doi: 10.1089/jop.2024.0019.
    PubMed     Abstract available


  65. VARDAR C, George-Weinstein M, Getts R, Byrne ME, et al
    Evaluation of Dose-Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts.
    J Ocul Pharmacol Ther. 2024 Jun 20. doi: 10.1089/jop.2024.0024.
    PubMed     Abstract available


  66. LIU L, Wang S, Blanco T, Ge H, et al
    Neurokinin-1 Receptor Antagonism Reduces Nonallergic Ocular Redness in a Rabbit Model.
    J Ocul Pharmacol Ther. 2024 Jun 3. doi: 10.1089/jop.2024.0003.
    PubMed     Abstract available


  67. LEE SS, Nagar S, Rajagopalan L, Orilla W, et al
    Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation.
    J Ocul Pharmacol Ther. 2024;40:297-308.
    PubMed     Abstract available


  68. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:259-260.
    PubMed    


    May 2024
  69. ANDERSON SG, Meyer D, Decloedt EH
    The Ocular Penetration and Intraocular Pressure Lowering Effect of Topical Acetaminophen in the New Zealand White Rabbit.
    J Ocul Pharmacol Ther. 2024 May 27. doi: 10.1089/jop.2024.0020.
    PubMed     Abstract available


  70. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:203.
    PubMed    


    April 2024
  71. GUO M, Liu T, Miao Y, Pan X, et al
    Role of NADPH Oxidase 4 on Dry Eye Syndrome in Mice.
    J Ocul Pharmacol Ther. 2024 Apr 26. doi: 10.1089/jop.2024.0002.
    PubMed     Abstract available


  72. NERI P, Perez Y, Agarwal A, Pichi F, et al
    Unraveling the Complexities of Severe Acute Respiratory Syndrome Coronavirus 2: A Comprehensive Ophthalmic and Systemic Perspective.
    J Ocul Pharmacol Ther. 2024 Apr 25. doi: 10.1089/jop.2024.0037.
    PubMed     Abstract available


  73. BISEN AC, Srivastava S, Mishra A, Sanap SN, et al
    Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery.
    J Ocul Pharmacol Ther. 2024 Apr 23. doi: 10.1089/jop.2023.0166.
    PubMed     Abstract available


  74. ANAM A, Liu C, Tong L, Liu YC, et al
    Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain.
    J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0155.
    PubMed     Abstract available


  75. GONZALEZ VH, Uram M, Schupp A, Widmann M, et al
    AG-920 (Articaine) Ophthalmic Solution: A Masked, Active-Controlled Evaluation of Its Local Anesthetic Efficacy and Safety in Pediatric Patients.
    J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0187.
    PubMed     Abstract available


  76. TRAN HDM, Ha TTX, Tran YH, Coroneo M, et al
    Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
    J Ocul Pharmacol Ther. 2024 Apr 15. doi: 10.1089/jop.2023.0173.
    PubMed     Abstract available


  77. HUSAIN S, Obert E, Singh S, Schnabolk G, et al
    Inhibition of HDAC1 and 3 in the Presence of Systemic Inflammation Reduces Retinal Degeneration in a Model of Dry Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2024 Apr 12. doi: 10.1089/jop.2023.0163.
    PubMed     Abstract available


  78. YADAV KS, Bisen AC, Ishteyaque S, Sharma I, et al
    Solanum nigrum Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model.
    J Ocul Pharmacol Ther. 2024 Apr 11. doi: 10.1089/jop.2023.0089.
    PubMed     Abstract available


  79. MISHRA A, Agrawal M, Tripathi A, Bhirud A, et al
    A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
    J Ocul Pharmacol Ther. 2024 Apr 10. doi: 10.1089/jop.2023.0186.
    PubMed     Abstract available


  80. DIAS PB, Rodrigues Parchen MDA, Wasilewski D
    Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement.
    J Ocul Pharmacol Ther. 2024 Apr 8. doi: 10.1089/jop.2023.0148.
    PubMed     Abstract available


  81. GARWEG JG, Pietzuch M, Mantel I, Ambresin A, et al
    Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".
    J Ocul Pharmacol Ther. 2024;40:199-200.
    PubMed    


  82. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:158-159.
    PubMed    


  83. WATANABE M, Sato T, Umetsu A, Nishikiori N, et al
    Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor-beta2 or Dexamethasone.
    J Ocul Pharmacol Ther. 2024;40:189-196.
    PubMed     Abstract available


  84. GAO J, Wang Y, Han R, Li J, et al
    Elevated KDM4D Expression in Pterygium: Impact and Potential Inhibition by Lycium Barbarum Polysaccharide.
    J Ocul Pharmacol Ther. 2024;40:181-188.
    PubMed     Abstract available


    March 2024
  85. CHENG Y, Liu G
    Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model.
    J Ocul Pharmacol Ther. 2024 Mar 28. doi: 10.1089/jop.2023.0154.
    PubMed     Abstract available


  86. CID-BERTOMEU P, Vilaltella M, Martinez M, Mir M, et al
    Topical Insulin for Ocular Surface Disease.
    J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2024.0016.
    PubMed     Abstract available


  87. MURAKAMI Y, Imaizumi T, Hashizume K, Tezuka Y, et al
    Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.
    J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2023.0141.
    PubMed     Abstract available


  88. YILMAZ OF, Sarmis A
    Relationship Between Conjunctival Corynebacterium and 5% Sheep Blood Agar.
    J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0010.
    PubMed    


  89. COLUCCIELLO M
    Steroid/AntiVascular Endothelial Growth Factor Combination Therapy for Neovascular Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0013.
    PubMed    


  90. LEE JH, Kim JH
    Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2024;40:136-143.
    PubMed     Abstract available


  91. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:109-110.
    PubMed    


  92. FIGUS M, Giansanti F, Villani E, Alio JL, et al
    Chloroprocaine 3% Gel as a Novel Ocular Topical Anesthetic: Results from a Multicenter, Randomized Clinical Trial in Patients Undergoing Cataract Surgery.
    J Ocul Pharmacol Ther. 2024;40:117-125.
    PubMed     Abstract available


    February 2024
  93. RUAN M, Wang R, He Y
    Novel Drug Delivery Systems for the Management of Fungal Keratitis.
    J Ocul Pharmacol Ther. 2024 Feb 23. doi: 10.1089/jop.2023.0161.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ophthalmology is free of charge.